Nirsevimab demonstrated protection against respiratory syncytial virus disease in healthy infants in Phase 3 trial - GlobeNewswire
Nirsevimab demonstrated protection against respiratory syncytial virus disease in healthy infants in Phase 3 trial GlobeNewswire
Comments
Post a Comment